Rare diseases
Investigational molecules
Locations
Study on Pembrolizumab for Patients with Localized Non-Metastatic MSI/dMMR Tumors or EBV+ Gastric Cancer
FranceStudy on Tebentafusp and Drug Combination for Patients with Advanced Uveal Melanoma
BelgiumStudy of Pembrolizumab, Pemetrexed, and Carboplatin for Patients with Advanced Stage Non-Small Cell Lung Cancer (NSCLC)
The NetherlandsStudy of Pembrolizumab for Patients with Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
ItalyStudy of EOS884448, Dostarlimab, and Inupadenant for Patients with Advanced Solid Tumors
BelgiumStudy on Dacarbazine, Pembrolizumab, Nivolumab, and Ipilimumab for Patients with Unresectable or Metastatic Melanoma Resistant to Immunotherapy
GermanyStudy Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
AustriaStudy on Patient Preference for Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Melanoma, Renal Cell Carcinoma, and Lung Cancer Patients
FranceStudy on Pembrolizumab, Etoposide, and Cisplatin or Carboplatin for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer
AustriaStudy on Binimetinib, Encorafenib, and Pembrolizumab for Patients with BRAF V600 Mutation-Positive Melanoma and Brain Metastasis
FranceStudy of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin
BelgiumStudy of Pembrolizumab and Chemotherapy for Patients with Recurrent Platinum-Sensitive Low-Grade Serous Ovarian Cancer
GermanyTell us about your condition – we search every trial in Europe and connect you with the right site.
